3M™ Harvest RC - Powering Single Stage Clarification

<p>Producing mAbs consistently at commercial scale is both a complex and expensive process with sales per gram ranging from $1,000 to $50,000 depending on the dosage. Such high costs and variability has put biopharmaceutical companies under pressure to improve manufacturing plant productivity (5&ndash;10 gram/liter).</p> <p>Biopharmaceutical companies have rapidly adopted single use technologies to increase flexibility on batch volumes (2000&ndash;6000 L, depending on the application), decrease capital cost, and reduce footprint because of their improved designs. Limitations around scaling capacity and articulate purification requirements pose risk factors as the latter is critical in the final protein manufacturing steps where no further filtration is present.</p> <p>This paper outlines the value proposition of <a href="https://www.bioprocessonline.com/doc/m-harvest-rc-chromatographic-clarification-solution-0001" target="_blank">3M&trade; Harvest RC technology</a>, a platform that allows the clarification and polishing train from discovery to commercial manufacturing to be simplified in a more intuitive way.</p> <p><em>Originally published by Frost &amp; Sullivan</em></p>